• Composition
  • Release form
  • Indication
  • Reception scheme
  • Contraindications
Active substance: nalbuphine; 1 ml of solution for injection contains nalbuphine hydrochloride in terms of 100% substance 10 mg; excipients: citric acid, sodium citrate, sodium metabisulfite (E 223), sodium chloride, concentrated hydrochloric acid, water for injection.
10 ampoules in a cardboard box, 1 ml in an ampoule
Pain syndrome of severe and moderate intensity; as an additional tool during anesthesia to reduce pain in the pre- and postoperative period; pain relief during childbirth.
The drug is prescribed for subcutaneous, intravenous and intramuscular administration. The dosage should correspond to the intensity of pain, the physical condition of the patient and take into account the interaction with other drugs used simultaneously. Usually, in case of pain syndrome, it is administered subcutaneously, intravenously or intramuscularly from 0.15 to 0.3 mg per 1 kg of the patient's body weight; a single dose is administered, if necessary, every 4-6 hours. The maximum single dose is 0.3 mg per 1 kg of body weight, the maximum daily dose is 2.4 mg / kg of body weight. In myocardial infarction, 20 mg administered slowly intravenously is often sufficient, but an increase in dose to 30 mg may be required. In the absence of a clear positive dynamics of pain syndrome - 20 mg again after 30 minutes. For premedication: 100-200 mcg / kg body weight. When carrying out intravenous anesthesia for the introduction of anesthesia - 0.3-1 mg / kg for 10-15 minutes, to maintain anesthesia - 250-500 μg / kg every 30 minutes. For pain relief during childbirth, the drug should be used in a dose of 20 mg intramuscularly. The drug is prescribed with caution to elderly patients, with general exhaustion, insufficient respiratory function.
Hypersensitivity to nalbuphine hydrochloride or any of the ingredients of the drug. Age under 18. The drug Nalbaxone should not be used in case of respiratory depression or severe depression of the central nervous system, increased intracranial pressure, head trauma, acute alcohol intoxication, alcoholic psychosis, obvious impairment of liver and kidney function. The combined use of the drug with pure antagonists of morphinomimetics and simultaneous treatment with μ-agonists of drugs (for example, morphine or fentanyl) is not recommended. It is not recommended to use the drug without appropriate diagnostics for surgical abdominal syndrome, since nalbuphine can mask its manifestations. The drug Nalbaxone should not be used by women during breastfeeding (except when used during childbirth).
Price information